New therapeutic strategies against carcinoma metastasis

Research

Although cancer survival rates have significantly improved in recent years, progress in cancer metastasis treatment has been limited. Most malignant tumours are carcinomas arising from the epithelial cells transformations. At early stages of carcinoma progression, epithelial cells can undergo a process called epithelial-to-mesenchymal transition, priming their migration from the primary tumour, eventually leading to their dissemination and metastasis initiation.

Aim

  • To develop novel small-molecule inhibitors targeting epithelial-to-mesenchymal transition, in order to combat tumour progression and carcinoma metastasis.

Problem to Solve

Cancer metastasis is the major cause of cancer morbidity, and accounts for around 90% cancer-related deaths. Metastasis prevention and treatment is one the most crucial challenges in cancer research. There is an urgent need to develop novel therapeutic approaches for metastatic cancer patients. Current treatments for cancer metastasis are mainly chemotherapy and radiotherapy, with show limited success depending on the type and stage of the disease.

Innovation

A new drug target involved at early stages of carcinoma progression and metastasis represents a new therapeutic approach with a novel mechanism of action. Moreover, the specificity of the drug target avoids broader site effects in pre-clinical studies. The use of novel small-molecules compounds against this drug target inhibits both carcinoma metastasis and tumor growth.

Team

Project leader. Research Group Leader

Angélica Figueroa Conde-Valvís

Instituto de Investigación Biomédica A Coruña

Project leader

PhD Student

Alba Casas Pais

Instituto de Investigación Biomédica A Coruña

PhD Student

Andrea Díaz Díaz

Instituto de Investigación Biomédica A Coruña

PhD Student

Daniel Roca Lema

Instituto de Investigación Biomédica A Coruña

Technology Transfer and Innovation Manager

Graciela Fernández Arrojo

Instituto de Investigación Biomédica A Coruña

MENTOR

CEO at Aelix Therapeutics

José Luis Cabero

Aelix Therapeutics & Symbiokraft

Partners

Obra social “la Caixa”
Caixa Capital Risc
Validate-19

Scientific Area

Clinical sciences

Business area

Therapeutic

Research center

Fundación Profesor Novoa Santos